Stifel Nicolaus Downgrades Synta Pharma. (SNTA) to Sell
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St set for higher open but weekly losses loom
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Supermicro probe finds no senior management link to export violations
- SpaceX shares fall as second lockup period ends
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
BMO Capital Downgrades Synta Pharma. (SNTA) to Underperform
March 12, 2014 6:25 AM EDTBMO Capital analyst Jim Birchenough downgraded Synta Pharma. (NASDAQ: SNTA) from Market Perform to Underperform and slashed his price target to $1 after weak Q1 results. The analyst notes limited cash, CEO departure and questionable direction.
Birchenough said, "With the extension of the timelines... More
Synta Pharma (SNTA) Ganetespib Selected for Study in I-SPY 2 TRIAL
March 11, 2014 7:05 AM EDTSynta Pharmaceuticals Corp. (NASDAQ: SNTA) and QuantumLeap Healthcare Collaborative announced that Syntas lead drug candidate, the Hsp90 inhibitor ganetespib, has been selected for study in the I-SPY 2 TRIAL (Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging And moLecular Analysis 2). I-SPY 2 is a standing phase 2 randomized, controlled, multicenter trial for women with newly diagnosed, locally advanced breast cancer (Stage 2 or higher) that is designed to test whether adding investigational drugs to standard chemotherapy is better than standard chemotherapy alone in the neo-adjuvant setting (prior to surgery).
The I-SPY 2 TRIAL... More
